Jay Brown, MD
Allergy & Immunology · Ames, IANPI 1790772069
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.6% of the total across 20 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AstraZeneca at 25.5% of the total. Reporting peaked in 2021 at $225 and has fallen 90.8% since, to $21 in 2025. That places this record below the midpoint for allergy & immunology clinicians in IA, where the typical reported total is $750.
Across 20 payments — averaging $31.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$159
- GSK$111
- Sanofi$106
- Biocryst US Sales Co., LLC$76
- Amgen$64
- Novo Nordisk$51
- plus $58 from 3 others
Across 117 payments — averaging $5709.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$630K
- AstraZeneca$33K
- Astrazeneca UK Limited$4K
- Alk-abello, Inc$1K
What the payments were for
- Food & beverage$60898%
- Education$152%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $159 |
| GSK | 2 | $111 |
| Sanofi | 6 | $106 |
| Biocryst US Sales Co., LLC | 1 | $76 |
| Amgen | 2 | $64 |
| Novo Nordisk | 3 | $51 |
| Octapharma USA, Inc. | 1 | $21 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $21 |
| Pfizer | 1 | $15 |
How this compares
$623 in reported general payments places this provider in the 45th percentile of 32 allergy & immunology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Advair HfaFluticasone Propion/Salmeterol | 223 | $104,878 |
| NucalaMepolizumab | 15 | $64,244 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 85 | $59,266 |
| Dupixent PenDupilumab | 13 | $50,811 |
| Spiriva RespimatTiotropium Bromide | 63 | $48,138 |
| DuleraMometasone/Formoterol | 66 | $27,125 |
| Breo ElliptaFluticasone/Vilanterol | 54 | $21,600 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 29 | $20,851 |
| SymbicortBudesonide/Formoterol Fumarate | 43 | $16,275 |
| Fluticasone Propionate HfaFluticasone Propionate | 23 | $8,171 |
| Azelastine Hcl | 194 | $5,749 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $5,337 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 179 | $5,162 |
| Arnuity ElliptaFluticasone Furoate | 19 | $4,363 |
| Theophylline ErTheophylline Anhydrous | 47 | $4,353 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $111 | $154,810185 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $159 | $37,12672 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 32 allergy & immunology providers in Iowa.
Other allergy & immunology in Ames
- Edward NassifAmes$5K
- Jason CascioAmes$844
- Vuong NayimaWest Des Moines$34K
- Fadi AlkhatibWest Des Moines$16K
- Daniel HamilosMason City$11K
- Lyla SchweigerCedar Rapids$6K
- Holly BrownCedar Rapids$4K
- Whitney MolisDes Moines$4K
- Safia NawazDes Moines$4K
- Andrea JonesDavenport$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.